首页> 外文期刊>RSC Advances >Design, synthesis, in vitro and in vivo evaluation of tacrine–cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease
【24h】

Design, synthesis, in vitro and in vivo evaluation of tacrine–cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease

机译:他克林-肉桂酸杂种作为阿尔茨海默氏病多靶点乙酰基和丁酰胆碱酯酶抑制剂的设计,合成,体外体内评估

获取原文
       

摘要

Previously, we have reported tacrine–ferulic acid hybrids as multi-target cholinesterase inhibitors against Alzheimer's disease. However, the detailed structure–activity relationship (SAR), especially regarding the ferulic acid moiety, has yet to be elucidated. Herein we report the structural modification of the ferulic acid moiety, which is replaced by cinnamic acid with different substitutions. The target compounds are synthesized and evaluated for their in vitro cholinesterase inhibitory activities, inhibition of amyloid β-protein self-aggregation, cyto-protective effects against hydrogen peroxide and antiproliferative activity in PC-12 cells. The optimal compounds 35 and 36 are subsequently selected for in vivo assays. 36 shows much better performance in ameliorating the scopolamine-induced cognition impairment and less hepatotoxicity than tacrine. The compound serves as a good lead compound for further optimization.
机译:以前,我们已经报道了他克林-阿魏酸杂种作为对抗阿尔茨海默氏病的多靶点胆碱酯酶抑制剂。但是,尚未阐明详细的构效关系(SAR),尤其是关于阿魏酸部分。在这里,我们报道了阿魏酸部分的结构修饰,其被具有不同取代的肉桂酸替代。合成了目标化合物,并评估了它们在体外对胆碱酯酶的抑制活性,对淀粉样β蛋白自我聚集的抑制作用,对过氧化氢的细胞保护作用以及对PC-12细胞的抗增殖活性。随后选择最佳化合物35和36用于体内分析。图36显示出比他克林更好的改善东pol碱诱导的认知障碍的性能,并且肝毒性更低。该化合物可作为进一步优化的良好先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号